Avastin disappointing in cancer studies
The drug avastin, which recently lost approval for treating breast cancer, now looks disappointing in treating ovarian cancer as well.
Two studies have found it does not improve survival for most ovarian cancer patients and keeps their disease from worsening for only a few months.
European regulators approved avastin for ovarian cancer last week, but the drug’s maker says the results of the studies do not make U.S. approval likely.
There have also been serious concerns about it causing adverse side effects.
